Search

everythinglearnresearchcommunity

for

Search:↓

Low-level laser therapy (LLLT) stimulates hair growth but current devices are expensive. A proposed non-profit project aims to create affordable, 3D-printed LLLT devices and collect data on their effectiveness.

SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.

The conversation discusses the use of topical spironolactone for hair loss, with the original poster applying 8 ml daily but learning that 2 ml is recommended. It also touches on hair transplants and the role of DHT sensitivity in hair loss, emphasizing individual differences in treatment outcomes.

The conversation discusses obtaining an online EU prescription for Bimatoprost/Lumigan for hair loss without an in-person doctor visit. The user is seeking alternatives to physical consultations for this treatment.

The conversation is about finding a clearnet vendor for clascoterone, also known as Winlevi, for hair loss treatment. The user is seeking recommendations via direct message.

The user is using oral minoxidil for hair growth and is considering adding topical latanoprost, but is concerned about potential eye color change. They are seeking advice on the effectiveness of latanoprost for hair thickening and the risk of eye color change.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

A user with androgenetic alopecia is using 8 ml of 1.4% topical spironolactone solution daily but is unsure if this amount is excessive, as 2 ml is more typical. They seek advice on the appropriate amount to apply.

Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.

The conversation is about updates on hair loss treatments Breezula or PTD-DBM. No new information was provided.

Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.

Bicalutamide and spironolactone are being compared for their effectiveness and safety in treating female pattern hair loss. The conversation seeks advice on which is better to use.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

Cbum's hair transplant is criticized for looking unnatural and not blending well, with some suggesting better results were expected given his resources. Discussions also cover the effects of steroids and finasteride on hair loss and muscle growth.

Hair loss discussion includes Latanoprost as potential treatment. Mild improvement observed with its use.

Pelage Pharmaceuticals received $120 million in Series B funding for hair loss treatment development. The conversation expresses excitement and anticipation for the release and effectiveness of the treatment.

Capilia Longa is considered as an alternative to Minoxidil for beard growth, with some users reporting positive results. However, concerns exist about its effectiveness and high cost, especially for scalp use.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

Scientists discovered a potential baldness treatment from hairy moles, which can be injected like Botox. Users discussed the treatment's implications, including its safety and effectiveness.

Prostaglandin balance affects hair loss, particularly in conditions like Lichen Planopilaris, where an imbalance can lead to hair follicle damage. Treatments mentioned include prostaglandin analogs and Pioglitazone HCL, with a focus on maintaining prostaglandin equilibrium for potential hair regrowth.

Fatty acid metabolic signaling can activate epithelial stem cells for hair regeneration. Oleic and palmitoleic acids showed the best results, but practical application on humans remains uncertain.

OP is considering adding topical bimatoprost or latanoprost to their hair loss treatment, which already includes oral minoxidil, and is seeking reliable sources for these products. Users discuss the effectiveness and sourcing of these treatments, with some using bimatoprost for both hairline and eyelashes, and others planning to use latanoprost mixed with finasteride.

Breezula's phase 3 enrollment for hair loss treatment is complete, but results have not been published, causing skepticism about its progress. Some users express doubt about its future, suggesting it may be reserved for exclusive use.

The user started using topical latanoprost and dutasteride, experiencing significant hair shedding and scalp itchiness, possibly due to an allergic reaction. They are considering stopping the treatment if the shedding is linked to an allergy.

A user reported positive hair growth using a regimen of oral finasteride, minoxidil, Dr. Pen, keto shampoo, and a Capillus 272 LLLT cap. Other users debated the effectiveness of the LLLT cap, with some attributing the success to the combined treatments rather than the cap alone.

Fluridil, also known as Topilutamide or Eucapil, is discussed as a treatment for hair loss. It is noted as an androgen receptor antagonist, not a vasodilator.

The conversation discusses the progress of Clascoterone (Breezula) for hair loss treatment, noting that COVID-19 delayed female trials by three months but Phase III trials for males are proceeding with a Special Protocol Assessment filed with the FDA. Users express hope for Breezula as an alternative to existing treatments like finasteride and minoxidil, despite concerns about its potential high cost.

Pelage, backed by Google Ventures, is seen as a promising company potentially finding a cure for hair loss using stem cell activation. There is skepticism and optimism among users, with some awaiting results from ongoing trials.

The conversation discusses using scalp antiandrogens like RU58841, pyrilutamide, or fluridil on the face to reduce sebum production, noting that clascoterone (winlevi) is an approved facial antiandrogen with underwhelming reviews.

PP405 is a promising new treatment for hair loss. It performs three actions in one, potentially offering a cure.